Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium (2016)

Peer-Reviewed Study · Seripa D; Solfrizzi V; Imbimbo BP; Daniele A; et al. · 2016

Seripa D et al., 2016: Independent review of tau-directed Alzheimer's therapies summarising that methylene blue (methylthioninium chloride) failed to show overall benefit in a 24-week phase 2 trial at 69-228 mg/day, and that the follow-up compound TRx0237 (leuco-methylthioninium) was claimed by its developers to be more bioavailable and less toxic.

A follow-up compound (TRx0237) claimed to be more bioavailable and less toxic than MT, is now being developed.

Seripa D et al., 2016: Independent review of tau-directed Alzheimer's therapies summarising that methylene blue (methylthioninium chloride) failed to show overall benefit in a 24-week phase 2 trial at 69-228 mg/day, and that the follow-up compound TRx0237 (leuco-methylthioninium) was claimed by its developers to be more bioavailable and less toxic. Study type: review.